Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban and tranexamic acid for bleeding and thrombosis management in intertrochanteric fracture surgery
ChiCTR1800018927Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tranexamic acid and rivaroxaban in intertrochanteric fracture and venous thromboembolism (VTE) (3 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Bleeding volume during operation, Bleeding volume after operation and 6 more. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
tranexamic acidrivaroxaban
03
Conditions
intertrochanteric fracturevenous thromboembolism (VTE)
Beyond the preview
Go deeper on ChiCTR1800018927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018927.